{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"AI Is About to Simulate Human Biology - Bioptimus","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/674ecc69acec010eef51a4ab/1778138396669-a6ce52ac-5884-494b-8b73-49178b8a14ba.jpeg?height=200","description":"

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.


Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed?


This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Bioptimus, with decades of experience spanning artificial intelligence, computational biology, academia and big tech, including leadership roles at Google, and work influenced by breakthroughs such as DeepMind’s AlphaFold.


In this episode, Jean-Philippe covers:


• Why Bioptimus is focused on understanding patient biology, not simply designing molecules, and why that could change drug development.


• How AI-powered decision systems could improve translational research, clinical trial design, patient recruitment and disease prediction.


• Why Jean-Philippe left Google to build Bioptimus, and why foundation models for biology may represent a major shift in medicine.


• How partnerships across healthcare systems, pharma and research institutions are helping build the data infrastructure behind biological foundation models, with perspectives shaped alongside leaders including Sarah Teichmann (Professor at Cambridge University) and Caroline Uhler (Professor at MIT)


• What makes AI in biology defensible, from proprietary data partnerships and elite interdisciplinary teams, to support from investors including Edward Kliphuis (Sofinnova Partners), Bpifrance, Cathay Investments.


A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading.


Be sure to check out the full episode.


Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent

TikTok: https://www.tiktok.com/@artotalent

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent


Jean-Philippe Vert

CEO at Bioptimus

LinkedIn: https://www.linkedin.com/in/jean-philippe-vert/


Lawrence Rose

Talent Solutions Director at ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/


Timestamps

00:00 Introduction and vision for AI as a universal simulator of biology

01:41 Introducing Jean-Philippe Vert and @Bioptimus

02:27 What Bioptimus is doing differently in AI biology

07:46 AI decision systems and improving clinical development

12:52 Early disease detection and predictive healthcare

15:28 Why Jean-Philippe left @Google

19:21 Building and sourcing biological data at scale

22:19 Partnerships and foundation models

28:04 Lessons from big tech

33:23 Defensibility in AI biology

37:09 Building interdisciplinary teams and culture

39:28 AI in healthcare, hype versus infrastructure

41:20 What AI means for doctors

43:10 What may define lasting AI-biology companies

45:05 Challenges of building Bioptimus

48:13 Prioritisation and deciding where to focus

51:33 Mentorship, leadership and building teams

53:02 Communicating vision to boards and investors

55:33 What success looks like in ten years


#LeadingBeyondTheLab #ARTOTalent #TechBio #ArtificialIntelligence #DrugDiscovery #ComputationalBiology #PrecisionMedicine

","author_name":"ARTO Talent"}